2,618 results on '"Morrow, Monica"'
Search Results
402. Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision
403. Reconstruction in Women with T4 Breast Cancer after Neoadjuvant Chemotherapy: When Is It Safe?
404. The Impact of Surgeon Referral and a Radiation Oncologist Productivity-Based Metric on Radiotherapy Receipt Among Elderly Women with Early-Stage Breast Cancer: Analysis from a Tertiary Cancer Network
405. Margin Width and Local Recurrence in Patients Undergoing Breast Conservation After Neoadjuvant Chemotherapy
406. Blood biomarkers reflect the effects of obesity and inflammation on the human breast transcriptome
407. Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
408. Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?
409. Postdischarge Nonsteroidal Anti-Inflammatory Drugs Are not Associated with Risk of Hematoma after Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia
410. Breast Conservation Among Older, Early-Stage Breast Cancer Patients: Locoregional Recurrence Following Adjuvant Radiation or Hormonal Therapy
411. Tumor-Nipple Distance of ≥ 1 cm Predicts Negative Nipple Pathology After Neoadjuvant Chemotherapy.
412. Customizing local and systemic therapies for women with early breast cancer:the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
413. Characteristics and Outcomes of Sentinel Node–Positive Breast Cancer Patients after Total Mastectomy without Axillary-Specific Treatment
414. Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer?
415. Is There a Low-Grade Precursor Pathway in Breast Cancer?
416. Cadherin–catenin complex dissociation in lobular neoplasia of the breast
417. A 10-Year Trend Analysis of Sentinel Lymph Node Frozen Section and Completion Axillary Dissection for Breast Cancer: Are These Procedures Becoming Obsolete?
418. Morbidity of Sentinel Node Biopsy: Relationship Between Number of Excised Lymph Nodes and Patient Perceptions of Lymphedema
419. Nipple-Sparing Mastectomy for Breast Cancer and Risk-Reducing Surgery: The Memorial Sloan-Kettering Cancer Center Experience
420. Receipt of Delayed Breast Reconstruction After Mastectomy: Do Women Revisit the Decision?
421. Morbidity of Sentinel Node Biopsy in Breast Cancer: The Relationship Between the Number of Excised Lymph Nodes and Lymphedema
422. Impact of Breast Density on the Presenting Features of Malignancy
423. Incidental Breast Lesions Identified by 18F-Fluorodeoxyglucose-Positron Emission Tomography
424. A prospective study of variability in mammographic density during the menstrual cycle
425. Outcome of axillary staging in early breast cancer: a meta-analysis
426. Predictors of Completion Axillary Lymph Node Dissection in Patients With Immunohistochemical Metastases to the Sentinel Lymph Node in Breast Cancer
427. What is an Adequate Margin for Breast-Conserving Surgery? Surgeon Attitudes and Correlates
428. Access to Breast Reconstruction After Mastectomy and Patient Perspectives on Reconstruction Decision Making
429. Margins in breast conservation: A clinicianʼs perspective and what the literature tells us
430. Social and Clinical Determinants of Contralateral Prophylactic Mastectomy
431. Margin Width is not Predictive of Residual Disease on Re-Excision in Breast-Conserving Therapy
432. Presenting Features of Breast Cancer Differ by Molecular Subtype
433. Predictors of Completion Axillary Lymph Node Dissection in Patients with Positive Sentinel Lymph Nodes
434. ASO Visual Abstract: Patient-Reported Outcomes in Patients Undergoing Lumpectomy With and Without Defect Closure.
435. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer
436. αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer
437. Presence of Lobular Carcinoma In Situ Does Not Increase Local Recurrence in Patients Treated with Breast-Conserving Therapy
438. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019
439. Cancer-specific mortality associated with germline genetic testing results among women with breast cancer or ovarian cancer treated with chemotherapy.
440. Does timing of chemotherapy impact breast satisfaction after breast conservation therapy and mastectomy with immediate reconstruction?
441. Reply to: “Ketorolac Following Mastectomy: Is There an Increased Risk of Reoperation?”
442. Retraction: Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women
443. Leptin Mediates Obesity-Induced DNA Damage in BRCA1 Breast Epithelial Cells
444. Is Residual Nodal Disease at Axillary Dissection Associated with Tumor Subtype in Patients with Low Volume Sentinel Node Metastasis After Neoadjuvant Chemotherapy?
445. Palpable Adenopathy Does Not Indicate High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer
446. ASO Author Reflections: Rethinking Palpable Adenopathy as a Marker of High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer
447. Tumor-Nipple Distance of ≥ 1 cm Predicts Negative Nipple Pathology After Neoadjuvant Chemotherapy
448. De-escalation of breast and axillary surgery in exceptional responders to neoadjuvant systemic treatment
449. Breast-conserving Surgery Without Radiation Therapy for Invasive Cancer
450. Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.